revenue
15.7–16.3 $billion
FY 2024
official guidance
| Revenue | $13.6B |
|---|---|
| Operating income | $1.2B |
| Net income | $1.3B |
| Free cash flow | $352.0M |
| Operating margin | 8.9% |
| Net margin | 9.4% |
| Return on equity | 17.3% |
| Period | TTM 2026-06-30 |
OpenFilings analyst
Agentic read of the latest earnings call — recommendation updates when we process a new transcript. Research synthesis, not investment advice.
Improving fundamentals are offset by modest underlying growth and material execution, leverage and pricing risks.
Latest call · Q2 2026Hold: Teva is executing a credible recovery, but the 2024 outlook implies only 2%-6% revenue growth excluding the $500 million Sanofi upfront payment, while adjusted EBITDA is guided to $4.5-$5.0 billion and adjusted EPS to $2.20-$2.50. AUSTEDO, UZEDY and AJOVY provide genuine growth, but North American generics are only expected to stabilize amid ongoing price erosion, launch competition and declining Truxima revenue; leverage remains elevated at 3.45x net debt/EBITDA.
AUSTEDO 2024 revenue guidance is $1.5 billion, following 27% growth to $1.2 billion in 2023; direct-to-consumer promotion and titration-pack improvements could support prescription growth.
UZEDY has 2024 revenue guidance of $80 million, with early uptake coming substantially from oral risperidone patients and additional switching within long-acting risperidone.
AJOVY has 2024 revenue guidance of $500 million after 16% growth in 2023.
Biosimilar Humira launch timing depends on FDA clearance of Alvotech's Iceland facility; management said there will be no Sanofi milestone payment in 2024.
Q4 2023 GAAP results benefited materially from the $500 million Sanofi upfront payment, making reported growth and margin comparisons less representative.
2024 revenue and earnings are expected to progress gradually, with the second half slightly higher than the first half.
Management targets AUSTEDO revenue of $2.5 billion by 2027 and expects five biosimilar launches over the next four years, including Stelara targeted for February 2025.
Teva plans 13 complex-generic launches in 2024-2025, but management explicitly acknowledged that several launches will face competition and are primarily intended to offset annual U.S. price erosion.
The 2027 framework calls for a 30% operating margin, mid-single-digit revenue growth and 2.0x net debt/adjusted EBITDA; achieving this depends on operating leverage after current investment in sales, marketing and R&D.
Olanzapine LAI is fully enrolled with 675 patients and 2,030 injections completed without a PDSS signal to date; Phase 3 results are expected in the second half of 2024 and could materially affect the pipeline thesis.
Debt reduction is progressing, with net debt down to $16.6 billion from $18.4 billion at year-end 2022, but approximately $3.4 billion matures around October 2026 and refinancing costs could remain high.
The planned TAPI divestiture should sharpen strategic focus, but management characterized its margin impact as broadly neutral rather than an immediate earnings catalyst.
Management declined to characterize North American generics as definitively growing, saying the outcome could be flat or growth depending on future price erosion and the number of competitors entering launches.
The 2024 revenue midpoint of $16.0 billion is only 4.3% above 2023 revenue excluding the Sanofi upfront payment, while operating expenses remain elevated at 27%-27.5% of revenue as Teva invests for future growth.
The Humira opportunity remains contingent on FDA approval of Alvotech's facility and uncertain PBM access; management acknowledged multiple variables around approval, launch timing and penetration.
A Q&A discussion disclosed errors in a contingent consideration liability and related expenses. Management said they were not material and did not affect non-GAAP results or cash flow, but a remediation plan for internal controls is still in progress.
North American generics remain exposed to structurally challenging pricing, and declining Truxima revenue adds pressure before the new complex-generic portfolio scales.
The call provided limited quantitative detail on Korlym's launch, the economics of the TAPI divestiture or the revenue contribution expected from individual biosimilars.
revenue
15.7–16.3 $billion
FY 2024
official guidance
revenue growth
2–6 pct
FY 2024
official guidance
gross margin
53–54 pct
FY 2024
official guidance
ebitda
4.5–5 $billion
FY 2024
official guidance
adjusted eps
2.2–2.5 $per share
FY 2024
official guidance
revenue
1.5 $billion
FY 2024
official guidance
revenue
0.08 $billion
FY 2024
official guidance
revenue
0.5 $billion
FY 2024
official guidance
revenue
2.5 $billion
FY 2027
management target
operating margin
30 pct
FY 2027
management target
OpenFilings analyst view from primary-source filings and earnings calls — not investment advice.
ALCOA CORPORATION
ALCOA CORPORATION
ALCOA CORPORATION
ALCOA CORPORATION
ALCOA CORPORATION
ALCOA CORPORATION
The rest of this company's wire — with summaries and source links — is part of Pro.
See plans